Double-blind randomised controlled trials have long been considered the benchmark for establishing the efficacy of a treatment. In these trials, both participants and researchers are intended to be unaware of the participants' actual treatment allocation. However, researchers rarely assess whether blinding has been maintained and, when they do, often only consider this issue at a superficial level.
In many trials that have taken this precaution, blinding was not actually achieved in that participants and/or assessors guessed the participants' treatment allocation better than chance [1, 2] . This often raises concerns regarding the validity of the trials' results. But the violation of blinding may not necessarily invalidate trials in which the active treatment appears more efficacious than placebo, as the probability of blinding being broken is likely to increase with the magnitude of the treatment's efficacy [3] . That is, if judgements about treatment allocation are based on treatment outcomes, the larger the treatment effect, the easier it will be for both participants and assessors to determine who is taking active medication. This produces the unsatisfactory situation whereby more efficacious treatments will be more difficult to assess using the double-blind procedure because there is a greater chance of blinding being broken.
Understanding this and other potential problems associated with the double-blind procedure requires a closer examination of the reasons why blinding is considered so important, especially those to do with participant expectancies. Expectancy can be a powerful determinant of health outcomes [4] [5] [6] . While the double-blind procedure is intended to control for expectancy effects, the extent to which expectancies mediate not only the individual participants' responses to the treatment within these trials but also the outcome of the trial itself remains largely unexplored.
The primary aim of the current analysis was to investigate whether participants' beliefs about treatment allocation predicted health outcomes independently of the treatment they actually received. The data were obtained from a clinical trial comparing naltrexone, acamprosate and a benign placebo for alcohol dependence. We hypothesised that those who believed they were taking active medication would demonstrate higher levels of abstinence, consume fewer alcoholic drinks, and have lower levels of alcohol dependence and cravings compared with those who believed they were on placebo. This data set is of particular interest in relation to placebo effects as the previous analysis failed to detect an effect of either drug [7] .
Methods

Participants
Participants were 169 alcohol-dependent patients who completed a trial comparing naltrexone and acamprosate for alcohol dependence [7] .
Design
The analysis was based on a 2 ! 2 between-subject design. The 4 treatment conditions (naltrexone, acamprosate, naltrexone placebo and acamprosate placebo) were simplified into either active medication or placebo and this constituted the first factor. The second factor was whether participants believed they were taking active medication or placebo.
Procedure
For a full description of the study procedure, see Morley et al. [7] . Briefly, participants were required to abstain from alcohol for a minimum of 3 days prior to a baseline assessment. They were then randomised to one of the four treatment conditions and received 12 weeks of pharmacotherapy accompanied by compliance therapy (4-6 sessions) involving exploring beliefs about alcohol dependence, the role of medication and addressing the need for treatment maintenance in relapse prevention [8] . During the treatment period, participants were asked to keep a diary to monitor their alcohol consumption and cravings. At the end of the 12 weeks a posttreatment assessment included a question regarding participants' perceived medication allocation.
Outcome Measures
The four primary outcome measures were cumulative days abstinent, cumulative alcoholic drinks, alcohol dependence and alcohol cravings. Alcohol dependence was assessed using the Alcohol Dependence Scale [9] and alcohol cravings were assessed using the Penn Alcohol Craving Scale [10] .
Data Analysis
2 ! 2 analysis of covariance tested the main effects of medication allocation, expectancy and their interaction. Age, sex, abstinence before the trial, alcohol dependence, average drinks per week pretreatment and number of pills involved were included as covariates. Additional contrast analyses compared main effects and their interaction on the number of counselling sessions attended and on self-efficacy ratings and readiness to change both before and after treatment. Although these additional contrasts were post hoc, no corrections to the error rate were made as this would have made these tests less conservative, in that a significant difference on any of these variables would undermine the potential explanatory power of expectancy for the observed results. 2 tests assessed blinding and compliance.
Results
As shown in figure 1 a, participants who believed they were taking active medication consumed 135 less drinks during the treatment period than those who believed they were taking placebo (F 1,106 = 9.6, p = 0.002). There was no main effect of treatment allocation on cumulative alcoholic drinks nor a significant interaction (both Fs ! 1). As shown in figure 1 b, there was also no effect of actual treatment allocation on alcohol dependence ratings nor was there a significant interaction (both Fs ! 1). However, those who believed they were taking active medication rated their alcohol dependency as 4.2 points lower than those who believed they were taking placebo. Similarly, participants who believed they were taking active medication rated their alcohol cravings as 5.4 points lower than those who believed they were taking placebo (both F 1,89 = 9.5, p = 0.003), as can be seen in figure 1 c. There was no main effect of actual treatment allocation on alcohol cravings nor a significant interaction (both Fs ! 1). For cumulative days abstinent, neither the main effects nor the interaction were significant (largest F 1,106 = 2.7, p = 0.10). Table 1 shows the distribution of participants according to the medication they expected and the medication they actually received. The trial successfully achieved blinding with participants unable to guess their medication allocation better than chance ( 2 2,116 = 2.92, p = 0.12). No significant differences were found for number of counselling sessions attended, number of days on medi-cation, readiness to change or self-efficacy ratings across both actual and perceived treatment allocation and their interaction.
Discussion
As previously reported [7] , there were no differences between those receiving active treatment and those receiving placebo. The new finding was that participants who believed they were taking active medication reported drinking less, being less alcohol dependent and craving alcohol less than those who believed they were taking placebo. These effects were substantial, especially for cumulative alcoholic drinks; participants who believed they were taking active medication consumed almost half the amount of alcohol over the 12 weeks than those who believed they were taking placebo. The lack of interaction between actual and perceived medication allocation indicates that the relationship between expectancy and treatment response was independent of the actual treatment the participants were receiving.
These findings highlight an important difference between double-blind placebo-controlled clinical trials and standard clinical practice. In standard practice, it is highly unlikely that a patient would doubt that he/she is receiving active medication, whereas in clinical trials the participant will validly question whether he/she is taking active medication or placebo [11] [12] [13] . If this corresponds to differences in expectancies regarding treatment outcome, then one might expect greater efficacy for the same treatment administered in standard clinical practice compared with double-blind trials. This possibility is supported by evidence that some treatments for major depressive disorder prove no better than placebo in double-blind trials despite showing robust effects in openlabel trials which tend to mimic clinical practice [14] . Mean + SE cumulative alcoholic drinks ( a ), alcohol dependence ratings ( b ) and alcohol cravings ( c ) for those who believed they had been taking active medication (expectancy) and those who believed they had been taking placebo (no expectancy). In each case, those who believed they had been taking active medication demonstrated better outcomes than those who believed they had been taking placebo, irrespective of the actual treatment they were receiving. In considering the relationship between blinding and trial outcome, there are a number of ways in which the double-blind procedure can be limited. The first occurs when the active treatment is truly more effective than placebo. In this case, blinding may be broken if the participants are able to observe the treatment effect and accurately guess their treatment allocation [3] . While this does not change the fact that the medication is more effective than placebo, it does reduce the trial towards a simple treatment versus no treatment comparison, rather than the intended treatment versus placebo comparison. The second case is when the outcome of the trial is that the active treatment is no better than placebo, as in the present case. If blinding is maintained, there is the possibility that the active treatment may, in reality, be better than placebo but that its effects were masked by expectancy effects. This may seem questionable given the common assumption that a placebo effect simply adds onto a treatment effect, but there are neither empirical nor theoretical reasons to support this view [15] .
In the current analysis, perceived, rather than actual, medication allocation predicted health outcomes. The lack of differences in compliance, number of counselling sessions, readiness to change and self-efficacy in those who believed they were taking active medication versus placebo suggests that these factors did not influence the findings and support a causal role for expectancy. However, because participants were asked about their perceived medication allocation at the end of the trial, it is impossible to determine whether they experienced improvement as a result of their belief that they were taking active medication or that they came to believe they were taking active medication because they experienced some improvement over the course of the trial.
The occurrence of adverse effects may also have impacted on participants' perceived medication allocation. That is, despite both drugs being ineffective as treatment, they may have produced some side effect that increased the likelihood of participants believing they were receiving active treatment. Although non-significant, the higher expectancy rate (69%) of those on medication compared with those on placebo (53%) partially supports this possibility. A point strengthened by evidence that antidepressants often appear less efficacious in trials employing active placebos, which intentionally produce adverse effects, compared with those employing inert placebos [16] .
In order to understand these issues more fully, future studies should develop and integrate more sophisticated techniques for evaluating the influence of participant expectancies within double-blind placebo-controlled trials. Rather than simple yes/no judgements, confidence ratings could be used to assess perceived medication allocation and could be incorporated several times during the trial [1, 4, 17] . Measuring expectancies at different time points throughout the trial would improve understanding of what influences beliefs about medication allocation, as well as enabling prospective analysis of their impact on health outcomes. Also, it would be useful to have qualitative analyses of participants' reasons for believing they are taking active medication or placebo. Such assessment of participant expectancies would allow for the inclusion of expectancies as a covariate within the analysis of a treatment's efficacy. This would be consistent with the basic rationale of double-blind randomised controlled trials: to determine the effect of the active medication independently of the effects of expectancy.
